Generate Biomedicines (GENB) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.74 billion vs $1.68 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | SEPN |
|---|---|---|
| Share price | $13.57 | $36.00 |
| Market cap | $1.74B | $1.68B |
| 1-day change | -1.67% | +0.93% |
| YTD return | — | +29.12% |
| 1-year return | — | +71.35% |
| EPS (TTM) | $-2.40 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $51.10 |
| 52-week low | $11.00 | $17.55 |
| Distance from 52-week high | -40.14% | -29.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +98.97% | +50.61% |
| Average volume | 1.04M | 383.90K |
| Shares outstanding | 128.35M | 46.68M |
| Employees | 312 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
GENB vs SEPN FAQ
Which is bigger, Generate Biomedicines or Septerna?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.74B compared with $1.68B for Septerna (SEPN).
Are Generate Biomedicines and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.